I usually ignore The State of the Union stuff. Too partisan on both sides! But I was glad to see unity vs Russian aggression. And Bi-partisan concern on CANCER and advancing non-opioid drugs and keeping drug prices reasonable(Insulin costs are outrageous! The discovers of Insulin refused to profit from it!)! On Covid, the virus will set the agenda! I expect to see Sorrento portfolio advancing nicely on at least 10 items!
1. Increasing COVISTIX sales as increased production allows for bidding on larger orders.
2. COVISTIX approvals in Canada and US, with sales following rapidly.
3. ABIVERTINIB(cancer) and PD-L1 marketing approvals in China.
4. COVI-MSC results from Brazil. If they are good they might wait for the US results and apply for EUAs in Brazil and US. Or they may just apply for Brazil approval and await the US results.
5. ABIVERTINIB approval for ARDS in intermediate Covid patients in Brazil.
6. COVIDROPS approval in UK and/or Mexico.
7. Mpro oral, broad spectrum anti-viral enters clinic. Will this be partnered?
8. SEMDEXA gains US FDA Breakthrough Designation. SCILEX deal advances!
9. RTX advances in phase 2 in cancer pain and arthritic knee pain.
10. SOFUSA advances in phase 2 autoimmune and cancer lymphatic drug delivery.
And the really big news would be a PARTNERSHIP! It is some 9 months since Sorrento announced they were seeking a worldwide ABIVERTINIB centered partnership. Or could there be a broader partnership/buyout agreement following the Genentech/Roche model? Big partnership often take 9-12 months to be completed. They can be complex and there could be several interested Big Pharma.
All of this could happen in Q1 or spill over into Q2. We will just have to wait...but I like our chances!
"The refusal of the real is the number one dogma of our time" Rene Girard
